Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121, USA.
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
非达霉素（FDX）是一种窄谱抗生素，最近的研究表明，它在治疗艰难梭菌感染方面优于万古霉素，能提供持续的临床应答。本研究检测了 FDX 及其主要代谢产物 OP-1118 的抗生素后效应（PAE）。结果显示，FDX 的 PAE 较长（ATCC 株为 10 h，临床分离株为 5.5 h），而 OP-1118 的 PAE 长于标准对照药万古霉素（分别为 3 h 和 0-1.5 h）。
